Bonesupport Holding AB (publ)

LSE:0RQO Stock Report

Market Cap: SEK 24.9b

Bonesupport Holding Valuation

Is 0RQO undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0RQO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
SEK 465.14
Fair Value
19.0% undervalued intrinsic discount
3
Number of Analysts

Below Fair Value: 0RQO (SEK376.8) is trading below our estimate of fair value (SEK465.14)

Significantly Below Fair Value: 0RQO is trading below fair value, but not by a significant amount.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0RQO?

Key metric: As 0RQO is barely profitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 0RQO. This is calculated by dividing 0RQO's market cap by their current revenue.
What is 0RQO's PS Ratio?
PS Ratio30.6x
SalesSEK 814.46m
Market CapSEK 24.89b

Price to Sales Ratio vs Peers

How does 0RQO's PS Ratio compare to its peers?

The above table shows the PS ratio for 0RQO vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average6.7x
GNS Genus
1.5x3.7%UK£970.9m
AVCT Avacta Group
8.3x0.4%UK£186.6m
OXB Oxford Biomedica
4.5x21.2%UK£434.3m
BVXP Bioventix
12.5xn/aUK£169.6m
0RQO Bonesupport Holding
30.6x33.5%SEK 24.9b

Price-To-Sales vs Peers: 0RQO is expensive based on its Price-To-Sales Ratio (30.6x) compared to the peer average (6.7x).

Price to Sales Ratio vs Industry

How does 0RQO's PS Ratio compare vs other companies in the GB Biotechs Industry?

5 CompaniesPrice / SalesEstimated GrowthMarket Cap
GNS Genus
1.5x3.7%US$1.19b
TRX Tissue Regenix Group
1.6x15.1%US$50.89m
VRCI Verici Dx
3.5x78.8%US$15.11m
DEST Destiny Pharma
3.5x-171.4%US$5.85m
0RQO 30.6xIndustry Avg. 8.0xNo. of Companies6PS01632486480+
5 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 0RQO is expensive based on its Price-To-Sales Ratio (30.6x) compared to the European Biotechs industry average (8x).

Price to Sales Ratio vs Fair Ratio

What is 0RQO's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0RQO PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio30.6x
Fair PS Ratio10.3x

Price-To-Sales vs Fair Ratio: 0RQO is expensive based on its Price-To-Sales Ratio (30.6x) compared to the estimated Fair Price-To-Sales Ratio (10.3x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0RQO forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentSEK 376.80
SEK 402.33
+6.8%
2.8%SEK 417.00SEK 390.00n/a3
Jan ’26SEK 391.60
SEK 402.33
+2.7%
2.8%SEK 417.00SEK 390.00n/a3
Dec ’25SEK 368.20
SEK 362.33
-1.6%
16.4%SEK 417.00SEK 280.00n/a3
Nov ’25SEK 336.90
SEK 345.67
+2.6%
16.2%SEK 417.00SEK 280.00n/a3
Oct ’25SEK 295.80
SEK 323.33
+9.3%
9.6%SEK 350.00SEK 280.00n/a3
Sep ’25SEK 301.59
SEK 323.33
+7.2%
9.6%SEK 350.00SEK 280.00n/a3
Aug ’25SEK 291.23
SEK 323.33
+11.0%
9.6%SEK 350.00SEK 280.00n/a3
Jul ’25SEK 271.41
SEK 297.67
+9.7%
4.6%SEK 313.00SEK 280.00n/a3
Jun ’25SEK 254.40
SEK 292.67
+15.0%
5.0%SEK 313.00SEK 280.00n/a3
May ’25SEK 226.00
SEK 292.67
+29.5%
5.0%SEK 313.00SEK 280.00n/a3
Apr ’25SEK 223.99
SEK 273.67
+22.2%
4.6%SEK 285.00SEK 256.00n/a3
Mar ’25SEK 195.83
SEK 257.00
+31.2%
7.2%SEK 280.00SEK 235.00n/a3
Feb ’25SEK 203.22
SEK 257.00
+26.5%
7.2%SEK 280.00SEK 235.00n/a3
Jan ’25SEK 188.50
SEK 245.50
+30.2%
4.3%SEK 256.00SEK 235.00SEK 391.602
Dec ’24SEK 175.71
SEK 245.50
+39.7%
4.3%SEK 256.00SEK 235.00SEK 368.202
Nov ’24SEK 148.29
SEK 166.50
+12.3%
3.9%SEK 173.00SEK 160.00SEK 336.902
Oct ’24SEK 127.50
SEK 166.50
+30.6%
3.9%SEK 173.00SEK 160.00SEK 295.802
Sep ’24SEK 123.70
SEK 166.50
+34.6%
3.9%SEK 173.00SEK 160.00SEK 301.592
Aug ’24SEK 144.89
SEK 166.50
+14.9%
3.9%SEK 173.00SEK 160.00SEK 291.232
Jul ’24SEK 127.60
SEK 154.00
+20.7%
9.1%SEK 168.00SEK 140.00SEK 271.412
Jun ’24SEK 118.30
SEK 154.00
+30.2%
9.1%SEK 168.00SEK 140.00SEK 254.402
May ’24SEK 102.22
SEK 141.50
+38.4%
18.7%SEK 168.00SEK 115.00SEK 226.002
Apr ’24SEK 83.50
SEK 141.50
+69.5%
18.7%SEK 168.00SEK 115.00SEK 223.992
Mar ’24SEK 86.58
SEK 141.50
+63.4%
18.7%SEK 168.00SEK 115.00SEK 195.832
Feb ’24SEK 87.85
SEK 123.50
+40.6%
6.9%SEK 132.00SEK 115.00SEK 203.222
Jan ’24SEK 80.45
SEK 123.50
+53.5%
6.9%SEK 132.00SEK 115.00SEK 188.502
Analyst Price Target
Consensus Narrative from 3 Analysts
SEK 400.84
Fair Value
6.0% undervalued intrinsic discount
3
Number of Analysts

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/11 11:25
End of Day Share Price 2025/01/10 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Bonesupport Holding AB (publ) is covered by 4 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Maria Vara FernándezBryan Garnier & Co
Kristofer Liljeberg-SvenssonCarnegie Investment Bank AB
Jonas PeciulisEdison Investment Research